Wedbush Issues Negative Forecast for Ardelyx Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Investment analysts at Wedbush decreased their Q2 2026 earnings per share estimates for Ardelyx in a report issued on Tuesday, July 15th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their previous estimate of $0.01. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx’s FY2026 earnings at $0.07 EPS, FY2027 earnings at $0.42 EPS, FY2028 earnings at $0.70 EPS and FY2029 earnings at $0.96 EPS.

Several other analysts have also recently commented on the company. HC Wainwright began coverage on Ardelyx in a report on Wednesday, June 18th. They set a “buy” rating and a $10.00 target price on the stock. Citigroup decreased their price target on Ardelyx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Wall Street Zen cut Ardelyx from a “hold” rating to a “sell” rating in a report on Monday, May 5th. Finally, Raymond James Financial cut Ardelyx from a “strong-buy” rating to an “outperform” rating and set a $11.00 price target on the stock. in a report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Ardelyx currently has an average rating of “Moderate Buy” and a consensus target price of $10.89.

Ardelyx Price Performance

Shares of ARDX stock opened at $4.60 on Wednesday. The stock’s fifty day moving average is $3.90 and its 200-day moving average is $4.72. The company has a debt-to-equity ratio of 1.04, a quick ratio of 3.81 and a current ratio of 4.12. The stock has a market capitalization of $1.10 billion, a PE ratio of -20.91 and a beta of 0.60. Ardelyx has a 52 week low of $3.21 and a 52 week high of $7.18.

Ardelyx (NASDAQ:ARDX) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.07). The business had revenue of $74.11 million for the quarter, compared to the consensus estimate of $79.40 million. Ardelyx had a negative return on equity of 34.45% and a negative net margin of 14.86%. Ardelyx’s revenue for the quarter was up 61.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.11) EPS.

Insider Transactions at Ardelyx

In related news, Director David M. Mott bought 381,377 shares of the business’s stock in a transaction on Friday, May 2nd. The shares were purchased at an average price of $4.22 per share, with a total value of $1,609,410.94. Following the completion of the purchase, the director owned 2,396,871 shares of the company’s stock, valued at $10,114,795.62. This represents a 18.92% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Justin A. Renz sold 7,218 shares of the firm’s stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $4.08, for a total value of $29,449.44. Following the sale, the chief financial officer directly owned 416,089 shares in the company, valued at approximately $1,697,643.12. This represents a 1.71% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 881,377 shares of company stock valued at $3,402,411 and have sold 125,143 shares valued at $517,667. Corporate insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

A number of hedge funds have recently modified their holdings of ARDX. GF Fund Management CO. LTD. acquired a new stake in shares of Ardelyx during the fourth quarter worth about $25,000. Cyndeo Wealth Partners LLC acquired a new stake in shares of Ardelyx during the first quarter worth about $49,000. Quarry LP acquired a new stake in shares of Ardelyx during the fourth quarter worth about $51,000. Rehmann Capital Advisory Group acquired a new stake in shares of Ardelyx during the fourth quarter worth about $51,000. Finally, Focus Partners Advisor Solutions LLC acquired a new stake in shares of Ardelyx during the first quarter worth about $56,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.